Strong Product Revenue
Product revenues for the second quarter totaled approximately $79 million, with $53 million from oral TPOXX and $26 million from IV TPOXX delivered to the U.S. Strategic National Stockpile. This fulfilled the $70 million of orders outstanding at year-end 2024.
Increased Development Funding
The company received $27 million in incremental development funding from the U.S. government, with $14 million allocated to manufacturing activities and $13 million to support the pediatric program.
Strong Financial Position
SIGA reported a pretax operating income of approximately $46 million for the quarter and maintained a cash balance of approximately $182 million with no debt as of June 30, 2025.
International Sales Success
Since 2020, SIGA has sold $135 million of oral TPOXX to 30 countries, showcasing the depth and scope of the international opportunity.